Page 1

Sangame Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results May 4 , 2021 THERAPEUTICS Conference Call and Webcast Scheduled for 5:00 p.m . Eastern Time BRISBANE , Calif .-- ( BUSINESS WIRE ) -- May 4 , 2021-- Sangamo Therapeutics , Inc. ( Nasdaq : SGMO ) , a genomic medicine company , today reported recent business highlights and first quarter 2021 financial results . " This quarter , we have continued our focus on advancing our lead programs through clinical execution , regulatory interactions , and collaborations with our partners and investigators . We are pleased that enrollment has completed for Pfizer's lead - in study for the hemophilia A Phase 3 AFFINE trial . Additionally , the EMA granted Orphan Designation and the FDA granted Fast Track Designation to BIVV003 , now known as SAR445136 , our cell therapy product candidate treating sickle cell disease partnered with Sanofi . Also , we initiated the STEADFAST study for our product candidate treating renal transplant rejection , which we believe is the first - in - human CAR - Treg clinical study , " said Sandy Macrae , Chief Executive Officer of Sangamo . " Further , our research engine continued to be highly productive this quarter , advancing both our CAR - Treg programs for autoimmune disorders and our transcriptional regulation therapies for neurological diseases . " Recent Business Highlights • Completed enrollment of patients in Pfizer's lead - in study to the registrational Phase 3 AFFINE clinical trial of giroctocogene fitelparvovec , a gene therapy product candidate for the treatment of severe hemophilia A , developed in collaboration with Pfizer . • Received Fast Track Designation from the FDA for BIVV003 , now known as SAR445136 , our cell therapy product candidate for the treatment of sickle cell disease , developed in collaboration with Sanofi . Also , the EMA granted Orphan Designation to SAR445136 based on early clinical data from three treated patients . • Initiated the Phase 1/2 STEADFAST clinical study evaluating TX200 , a wholly - owned autologous HLA - A2 CAR - Treg cell therapy product candidate treating patients receiving a HLA - A2 mismatched kidney from a living donor . The first patient is expected to be enrolled in this study by the end of this year . • Published preclinical data on tau- and alpha - synuclein - targeted zinc finger transcriptional repressors in Science Advances and at the 15th International Conference on Alzheimer's & Parkinson's Diseases ( ADPD ) , respectively . Also , announced upcoming preclinical alpha - synuclein and C9ORF72 abstracts to be presented at the upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy ( ASGCT ) on May 11 , 2021 . First Quarter 2021 Financial Results Consolidated net loss for the first quarter ended March 31 , 2021 was $ 45.9 million or $ 0.32 per share , compared to a net loss of $ 42.9 million or $ 0.37 per share for the same period in 2020 . Revenues Revenues for the first quarter ended March 31 , 2021 were $ 26.3 million , compared to $ 13.1 million for the same period in 2020. The increase of $ 13.2 million in revenues was primarily due to the recognition of upfront license fees and research reimbursements under our collaboration agreements with Biogen and Novartis , which became effective in April and July 2020 , respectively . These increases were partially offset by a decrease in revenue related to our hemophilia A collaboration with Pfizer , as a result of completion of our reimbursable activities in the fourth quarter of 2020 . GAAP and Non - GAAP operating expenses ( In millions ) Research and development = General and administrative Total operating expenses Stock - based compensation expense Three Months Ended March 31 , 2021 $ 56.5 $ 41.5 16.1 2020 72.6 16.1 57.6 ( 7.5 ) ( 5.6 )